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Summary
 
Systemic tolerance can be elicited by introducing antigen into an immune-privileged site, such
as the eye, or directly into the blood. Both routes of immunization result in a selective defi-
ciency of systemic delayed type hypersensitivity. Although the experimental animal model of
anterior chamber–associated immune deviation (ACAID) occurs in most mouse strains,
ACAID cannot be induced in several mutant mouse strains that are coincidentally deficient in
natural killer T (NKT) cells. Therefore, this model for immune-privileged site–mediated toler-
ance provided us with an excellent format for studying the role of NKT cells in the develop-
ment of tolerance. The following data show that CD1-reactive NKT cells are required for the
development of systemic tolerance induced via the eye as follows: (a) CD1 knockout mice
were unable to develop ACAID unless they were reconstituted with NKT cells together with
CD1
 
1
 
 antigen-presenting cells; (b) specific antibody depletion of NKT cells in vivo abrogated
the development of ACAID; and (c) anti-CD1 monoclonal antibody treatment of wild-type
mice prevented ACAID development. Significantly, CD1-reactive NKT cells were not re-
quired for intravenously induced systemic tolerance, thereby establishing that different mecha-
nisms mediate development of tolerance to antigens inoculated by these routes. A critical role
for NKT cells in the development of systemic tolerance associated with an immune-privileged
site suggests a mechanism involving NKT cells in self-tolerance and their defects in autoimmu-
nity.
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I
 
mmune privilege in the eye is attributed to various local
factors including the lack of lymphatic drainage (1), Fas
ligand expression (2), and multiple immunosuppressive fac-
tors in aqueous humor (3–6). In addition to local immuno-
suppression, ocular immune privilege is associated with the
development of an antigen-specific systemic immune devi-
ation. The mechanisms of immune deviation of the ocular
type are well studied in an experimental animal model
called anterior chamber–associated immune deviation
(ACAID)
 
1
 
 (7–9). ACAID is characterized by a selective de-
ficiency in delayed type hypersensitivity (DTH) and Ig iso-
types that fix complement (10, 11). ACAID is fashioned by
indigenous, intraocular bone marrow–derived APCs that
capture antigen within the anterior chamber (ac) and carry
an antigen-specific ACAID-inducing signal via the blood
directly to the spleen (10, 12).
The immune deviation induced via the ac is mediated by
unique negative regulatory T cells and T helper (Th) cells
that are generated in the spleen within 7 d after ac inocula-
tion. The antigen-specific regulatory T cells suppress both
the induction (CD4
 
1
 
 afferent–regulatory T cells) and the
expression (CD8
 
1
 
 efferent–regulatory T cells) of DTH (13,
14). The afferent regulators interfere with proliferation of
CD4 T cells that will be responsible for the DTH response.
Alternatively, the efferent-regulatory T cells inhibit the ca-
 
1
 
Abbreviations used in this paper:
 
 ac, anterior chamber; ACAID, anterior
chamber–associated immune deviation; B6, C57BL/6; DN, double nega-
tive; DTH, delayed type hypersensitivity; ES, embryonic stem; KO,
knockout; LAT, local adoptive transfer; PEC, peritoneal exudate cell;
R
 
a
 
AsGM1, rabbit antiasialo GM1; WT, wild-type. 
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pacity of CD4
 
1
 
 T cells to mediate DTH at the elicitation
site. In addition, there is a preponderance of CD4
 
1
 
 Th cells
with similarities to Th2-type cells that can be associated
with the transition to high titers of antigen-specific IgG1
antibodies observed in ACAID (15, 16).
Although ACAID occurs in most mouse strains, several
mutant mouse strains, including 
 
b
 
2-microglobulin knockout
(KO) mice (17), 
 
lpr
 
/
 
lpr
 
 mice (18), and SJL mice (Sonoda,
K.-H., and J. Stein-Streilein, unpublished data) fail to develop
ACAID and also display a deficit or dysfunction of NKT cells
(19–21). NKT cells belong to a specialized population of T
lymphocytes that coexpress the TCR 
 
a
 
/
 
b
 
 chain and NK
markers (22). About 85% of the mouse NKT cell population
express a restricted TCR repertoire consisting of an invariant
TCR 
 
a
 
 chain (V
 
a
 
14J
 
a
 
281 [23–25]). Similarly, NKT cells
exist in humans and express the invariant V
 
a
 
24J
 
a
 
Q TCR 
 
a
 
chain (26–29). NKT cells are restricted by MHC class I–like
CD1 molecules (29–31), and because the CD1 molecule is
also required for the development of NKT cells, CD1 KO
mice selectively lack NKT cells (32–34).
In this report, we show that NKT cells are absolutely re-
quired for the induction of immune deviation via the ocu-
lar but not the intravenous route of inoculation. Moreover,
the NKT cells must bind to the CD1 molecule to be able
to induce the development of the antigen-specific efferent-
regulatory T cells that participate in the immune deviation
mechanism.
 
Materials and Methods
 
Mice.
 
Female, 8–10-wk-old mice were used in all experiments.
C57BL/6 (B6) mice were obtained from Taconic Farms. (B6 
 
3
 
129/Sv) F1 (F1) mice were obtained from The Jackson Laboratory.
CD1 KO mice were generated in the Transgenic Facility, Harvard
Medical School, Boston, MA (Exley, M., manuscript submitted for
publication). In brief, the CD1 (both CD1.1 and CD1.2) mutation
was created in strain 129/Sv-derived embryonic stem (ES) cells.
Mutant ES cell clones were injected into B6 blastocysts to obtain
chimeric mice. Heterozygous mutant animals were intracrossed in
brother–sister mating to obtain (B6 
 
3
 
 129/Sv)F2 (F2) homozygous
mutants. In most cases, control wild-type (WT) mice were F2 mice
(The Jackson Laboratory), but F1 cells were used as WT in recon-
stitution experiments. A confirmatory experiment was performed in
B6 CD1 KO mice. During the time the experiments were per-
formed, the CD1 mutation was being backcrossed to the B6 parent
for five generations (N5). Progeny that lacked the CD1 gene as de-
termined by DNA analyses were chosen for breeders. The animals
were maintained on food and water ad libitum until they reached
the desired weight (20–24 g). All animals were treated humanely
and in accordance with the Schepens Eye Research Institute–Bos-
ton Biomedical Research Institute Animal Care and Use Commit-
tee and National Institutes of Health guidelines.
 
Induction of ACAID and Assay for DTH.
 
ACAID was in-
duced in mice by inoculating OVA (50 
 
m
 
g/2 
 
m
 
l in HBSS; Sigma
Chemical Co.) into the ac (10) 7 d before sensitizing subcutane-
ously for DTH. Intravenously induced immune deviation was in-
duced by inoculation of the antigen (OVA, 50 
 
m
 
g/100 
 
m
 
l in
HBSS) into the tail vein with a 30-gauge needle 7 d before im-
munizing for DTH. To induce DTH, mice received a subcuta-
neous inoculation with OVA (100 
 
m
 
g/ml in HBSS, 50 
 
m
 
l) emul-
 
sified in CFA (50 
 
m
 
l) and 1 wk later were tested for the
development of DTH by an intradermal inoculation of OVA-
pulsed peritoneal exudate cells (PECs; 2 
 
3
 
 10
 
5
 
/10 
 
m
 
l HBSS) into
the right ear pinnae. Ear swelling was measured 24 and 48 h later
with an engineer’s micrometer (Mitutoyo/MTI).
 
Local Adoptive Transfer.
 
To test for the efferent-regulatory
cell of ACAID, a modified local adoptive transfer (LAT) assay
was performed as described elsewhere (14). In brief, T (effector)
cells were generated in B6 mice or F1 (3–5) by immunizing sub-
cutaneously with OVA in HBSS and CFA. 7 d later the primed
T cells were enriched from dissociated spleen cells by removing B
cells and macrophages using IMMULAN™ columns (no.
BL7020; Biotecx Laboratories, Inc.). Regulator cells were simi-
larly enriched on IMMUNLAN™ columns from spleen cells of
ACAID mice 7 d after ac inoculation of OVA. Stimulator cells
were OVA-pulsed PECs as described below. Effector (5 
 
3
 
 10
 
5
 
),
stimulator (5 
 
3
 
 10
 
5
 
), and regulator (5 
 
3
 
 10
 
5
 
) cells were mixed
and resuspended in 10 
 
m
 
l HBSS for intradermal inoculation into
the right ear pinnae of naive mice. Ear swelling was measured
with an engineer’s micrometer at 24 and 48 h. As a negative con-
trol, naive T cells from nonmanipulated mice were used as effec-
tor cells and regulator cells. Primed T cells were used as effector
cells, and naive T cells from nonmanipulated mice were used as
regulator cells for positive control.
 
Preparation of OVA-pulsed PECs.
 
PECs were obtained from
peritoneal washes of mice 3 d after they received an intraperito-
neal inoculation of 2.5 ml of 3% aged thioglycolate solution
(Sigma Chemical Co.). After counting, PECs were cultured with
OVA (5 mg/ml) in a 24-well culture plate in serum-free medium
(RPMI 1640 medium, 10 mM Hepes, 0.1 mM nonessential
amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin, 100
 
m
 
g/ml streptomycin (BioWhittaker), and supplemented with
0.1% bovine serum albumin (Sigma Chemical Co.), ITS
 
1
 
 culture
supplement (1 
 
m
 
g/ml iron-free transferrin, 10 ng/ml linoleic acid,
0.3 ng/ml Na
 
2
 
Se, and 0.2 
 
m
 
g/ml Fe(NO
 
3
 
)
 
3
 
; Collaborative Bio-
medical Products). Nonadherent cells were removed from the
cultures after 18 h by three washes, and the remaining adherent
cells were collected by vigorous pipetting with cold medium
(4
 
8
 
C) before washing (three times in HBSS) to remove free OVA.
 
Abs.
 
The Abs used for flow cytometry analysis were as fol-
lows: Fc Block™ (anti–mouse FcR
 
g
 
 II/III mAb, 2.4G2), biotin
or FITC-conjugated anti-NK1.1 mAb (PK136), biotin-conju-
gated anti-Ly49C (5E6), biotin-conjugated anti-CD1 mAb
(1B1), FITC-conjugated anti-CD3 mAb (145-2C11), Cy-
Chrome 5–conjugated anti–TCR-
 
b
 
 mAb (H57-597) were all
purchased from PharMingen. PE-conjugated anti-B220 mAb
(RA3-6B2) and PE-conjugated Mac-1 (M1/70.15) were pur-
chased from CALTAG Laboratories. Rabbit antiasialo GM1 Ab
(R
 
a
 
AsGM1) was purchased from Wako Chemicals USA, Inc.;
streptavidin-PE was purchased from Jackson ImmunoResearch
Labs, Inc. and FITC-conjugated goat anti–rabbit IgG was pur-
chased from Sigma Chemical Co.
The Abs used for in vivo treatment were as follows: anti-
NK1.1 mAb (PK136, mouse IgG2a) and anti-Ly49C (5E6,
mouse IgG2a) were purified from mouse ascites using protein A
column chromatography (GIBCO BRL) in our laboratory. Puri-
fied mouse IgG was purchased from Sigma Chemical Co. for use
as control for anti-NK1.1 mAb and anti-Ly49C. R
 
a
 
AsGM1 was
purchased from Wako Chemicals USA, Inc., and purified rabbit
IgG was purchased from Sigma Chemical Co. Anti-CD1 mAb
(3C11, rat IgM) was also purified from mouse ascites using pro-
tein A columns. Purified rat IgM isotype control (R4-22) was pur-
chased from PharMingen and used as control for anti-CD1 mAb. 
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Flow Cytometry.
 
Splenic NK and NKT cells were analyzed
by flow cytometry. RBCs were lysed by adding Tris-buffered
ammonium chloride to a cell pellet of spleen cells. Staining was
performed in the presence of saturating concentration of Fc
Block™ (blocks FcR
 
g
 
 II/IIIs). Cells were stained with the fol-
lowing three reagents and colors (using concentrations recom-
mended by the manufacturer): biotin-conjugated anti-NK1.1
mAb counterstained with streptavidin-PE; CyChrome 5–conju-
gated anti–TCR-
 
b
 
 chain mAb; and FITC-conjugated anti-CD3
mAb. In some experiments the cells were stained with
R
 
a
 
AsGM1 Ab and counterstained with FITC-conjugated goat
anti–rabbit IgG and with CyChrome 5–conjugated anti–TCR 
 
b
 
chain mAb. Stained cells were analyzed on an EPICS XL flow
cytometer (Coulter). The absolute number of splenic NKT cells
detected in flow cytometry was calculated from the percent of
NKT cells in the number of viable cells. The total number of
viable cells harvested from the spleens before staining was deter-
mined by the trypan blue exclusion method.
 
Depletion of NK and NKT Cells In Vivo.
 
To deplete NK cells
in vivo, 100 
 
m
 
l of PBS containing one of the following
R
 
a
 
AsGM1 (250 
 
m
 
g), mouse anti-NK1.1 Ab (50 
 
m
 
g), rabbit IgG
(250 
 
m
 
g), or mouse IgG (50 
 
m
 
g) was injected into the tail vein of
B6 mice. To deplete both NK and NKT cells in vivo, a mixture
of anti-NK1.1 mAb and anti-Ly49C (50 
 
m
 
g 
 
1
 
 50 
 
m
 
g) or mouse
IgG (100 
 
m
 
g) was injected into the tail vein of B6 mice. 24 h
later, spleen cells from Ab-treated animals were monitored for the
presence of NK or NKT cells by flow cytometry using Abs that
detected an NK marker that was different from the target of the
Ab used in the depletion treatment. 24 h after the cell depletion
treatments, B6 mice were inoculated ac with OVA (50 
 
m
 
g/2 
 
m
 
l).
7 d after ac inoculation, the ability to suppress a primed DTH re-
sponse was tested in a LAT assay. Before enriching for the regu-
lator T cells from spleens from the ac-inoculated mice, the NK
and NKT cells were monitored again to confirm their absence.
 
Blocking of NKT–CD1 Cell Interaction In Vivo.
 
Purified anti-
CD1 mAb (3C11) or control rat IgM mAb (50 
 
m
 
g in 100 
 
m
 
l
PBS) was injected into the tail vein of B6 mice to block the inter-
action of NKT cells with CD1. It is reported that 3C11 blocks
the NKT cell–CD1 interaction in vitro (31). Flow cytometry
studies of spleen cells from the 3C11-treated mice confirmed that
the CD1
 
1
 
 cells (biotin-conjugated anti-CD1 mAb [1B1] coun-
terstained by streptavidin-PE) were neither depleted nor showed
changes in the populations of T cells (FITC-conjugated anti-
CD3 mAb), B cells (PE-conjugated anti-B22 mAb), NK and
NKT cells (triple staining: FITC-conjugated anti-CD3 mAb,
CyChrome 5–conjugated anti–TCR 
 
b
 
 chain mAb, and biotin-
conjugated anti-NK1.1 mAb counterstained by streptavidin-PE),
and macrophages (PE-conjugated Mac-1) (data not shown).
 
Depletion of NK1.1
 
1
 
 or CD1
 
1
 
 Cells In Vitro.
 
After RBC ly-
sis, spleen cells were treated with FITC-conjugated anti-NK1.1
mAb, biotin-conjugated anti-Ly49C, and MicroBeads-conju-
gated anti–mouse pan-NK cells (DX5) (Miltenyi Biotec), and
washed twice in PBS (pH 7.2) containing 0.5% BSA and 2 mM
EDTA. Ab-labeled cells were treated with anti-FITC Micro-
Beads and streptavidin MicroBeads (Miltenyi Biotec) for 15 min,
and washed twice. To harvest NK and NKT cell–enriched and
depleted populations, cells were applied to Type MS
 
1
 
 positive
selection column with MiniMACS (Miltenyi Biotec). Cells were
stained with Cy-Chrome 5–conjugated anti–TCR 
 
b
 
 chain mAb,
and depletion or enrichment was confirmed by flow cytometry.
Cell numbers of depleted populations were adjusted to approxi-
mate the number used in the control studies.
For reconstitution experiments, CD1
 
1
 
 cells were depleted
from the spleen cells. Following RBC lysis, column-enriched
splenic T cells were incubated with biotin-conjugated anti-CD1
(1B1) and then treated with streptavidin MicroBeads before they
were applied to Type MS
 
1
 
 positive selection column with Mini-
MACS. The CD1
 
1
 
 cell–depleted population in the effluent wash
was counterstained by streptavidin-PE (Jackson ImmunoResearch
Labs, Inc.) and analyzed by flow cytometry to confirm the quality
of the depletion technique.
 
Reconstitution of CD1 KO Mice.
 
CD1 KO mice were 
 
g
 
-irra-
diated (cesium, 500 rad, Mark 1 irradiator; J.L. Shepherd and As-
sociates) 1 d before receiving 2 
 
3
 
 10
 
7
 
/mouse whole spleen cells
derived from F1 mice or spleen cells depleted of their NK1.1
 
1
 
cells by magnetic beads. 7 d later, reconstituted CD1 KO mice
were inoculated (ac) with OVA (50 
 
m
 
g/2 
 
m
 
l in HBSS). Spleens
were removed 1 wk after the ac inoculation, dissociated cells
were pooled, and splenic T cells were enriched as described
above. Enriched splenic T cells were transferred to naive F1 mice
as regulator cells with effector (derived from F1 mice) and stimu-
lator cells (derived from F1 mice) prepared as described above
and tested in a LAT assay. Any host versus graft disease that might
have occurred was undetectable and did not interfere with the
experimental outcome 15 d after reconstitution.
 
Statistics.
 
Data were subjected to analysis by analysis of variance
and Scheffe’s test. A value of 
 
P
 
 
 
#
 
 0.05 was considered significant.
 
Results
 
ACAID Induction Correlates with an Increase in Splenic
NKT Cells.
 
ACAID is a well-established experimental
animal model for the study of immune deviation mediated
through an immune-privileged site. Modulation of the
model and analysis of the subsequent effects on the im-
Figure 1. Generation of ACAID correlates with increased number of
NKT cells in the spleen. ACAID was induced in mice as described previ-
ously. In brief, B6 mice were killed 7 d after ac inoculation of OVA. Col-
umn-enriched splenic T cells were harvested from ac-inoculated and un-
inoculated mice by application to IMMULAN™ columns, and stained for
analysis by flow cytometry to determine the ratio of NK and NKT cells
present within the lymphocyte gate for individual animals. Fluorescence for
the TCR b chain (CyChrome 5) and the NK1.1 marker (PE) are shown
on the ordinate and abscissa, respectively. The percentage of cells within
the NK cell quadrant (rectangle) and the NKT cell quadrant (square) are in-
dicated for the representative experiment shown. Absolute number (mean 6
SEM) of NK and NKT cells was calculated from the precounted viable cell
numbers in individual animals (n 5 5), and is shown below the abscissa.
Significant differences (P # 0.05) are indicated by an asterisk.1218 NKT Cells in Immune Deviation
mune deviation–associated systemic tolerance can be as-
sessed directly in the whole mouse, or in a LAT assay (14)
for detection of antigen-specific regulatory T cells associ-
ated with ACAID. The postulate that NKT cells are im-
portant in ACAID was first assessed by looking for an
ACAID-associated increase of NKT cells in the spleen.
B6 mice were inoculated (ac) with OVA, and 7 d later
the spleens were extirpated, cells dissociated, and the num-
bers of NK and NKT cells were analyzed by flow cytome-
try after staining for the TCR b chain and the NK1.1 mol-
ecule. Analysis was performed on five individual mice per
group. The flow cytometry data showed that the ratio of
NKT cells to total gated lymphocytes from spleens (de-
pleted of B cells and macrophages) was increased in all
ACAID mice compared with naive mice (Fig. 1), subcuta-
neously or intravenously inoculated mice (data not shown)
at 7 d after ac inoculation. In contrast to NKT cells, the
number of NK cells did not change in the spleen during
ACAID induction. Both the percent and the absolute
number of NKT cells in the spleen began to increase as
early as day 3 (data not shown), and peaked at day 7 (Fig.
1). These data show an association of splenic accumulation
of NKT cells, not NK cells, with the induction of ACAID.
CD1 KO Mice Failed to Induce ACAID. To directly test
the involvement of the NKT cells in the development of
ACAID, we examined the potential of CD1-deficient mice
Figure 2. ACAID in CD1 KO mice. (A) ACAID induction in CD1 KO mice. For clarity, the inset shows the ACAID protocol. Five CD1 KO mice and
five WT mice were inoculated (ac) with OVA 7 d before subcutaneous sensitization with OVA and CFA. Mice were challenged with OVA-pulsed PECs de-
rived from F1 mice into the ear pinnae 7 d after subcutaneous sensitization. Ear swelling measurements (24 h after ear challenge) are shown on the ordinate.
Treatment of the mice in each group represented by the bars is shown below the abscissa. Significant differences (P # 0.05) are indicated by an asterisk. (B)
Regulatory cell induction in CD1 KO mice. A LAT assay (inset shows the LAT protocol) was performed to assess the development of efferent regulatory T
cells. The black bar represents results using (B6 3 129)F2 CD1 KO mice. Column-enriched splenic T cells harvested from ac-inoculated WT mice or CD1
KO mice (five per group) 7 d earlier were used as regulator cells and cotransferred into F1 mice (five per group) with effector and stimulator cells from F1 mice.
The hatched bars represent results from similar studies using B6 KO and B6 mice. Ear swelling measurements (24 h after ear challenge) are shown on the ordi-
nate, and the mixture of cells inoculated into the ear pinnae is indicated below the abscissa. Significant differences (P # 0.05) are indicated by an asterisk.1219 Sonoda et al.
to develop immune deviation after ac inoculation of anti-
gen. Since the CD1 molecule is essential for NKT cell de-
velopment (30, 31), CD1 KO mice do not have NKT
cells, but do have NK cells and other lymphocyte subpopu-
lations (32–34). CD1 KO mice and control WT mice were
inoculated (ac) with OVA 7 d before subcutaneous sensiti-
zation with OVA and CFA, and challenged into the ear
pinnae with OVA-pulsed PECs 7 d after subcutaneous sen-
sitization (Fig. 2 A, protocol inset). When ear swelling was
measured 24 and 48 h later, it was observed that ac-inocu-
lated CD1 KO mice developed a positive DTH (ear swell-
ing) response, but ac-inoculated WT mice exhibited a sup-
pressed response (Fig. 2 A). While the level of the DTH
response in CD1 KO mice was similar to that in WT mice,
CD1 KO mice did not develop ACAID.
To further assess the NKT cell-dependent ACAID mech-
anism, spleen cells from ac-inoculated CD1 KO and WT
mice were tested in a LAT assay (Fig. 2 B, black bars, proto-
col inset). In brief, CD1 KO mice were inoculated (ac) with
OVA 7 d before harvesting, dissociating, and enriching T
cells from the spleens for use as regulator cells. Regulator T
cells were then cotransferred with OVA-primed T cells (ef-
fector cells from F1 mice) and OVA-pulsed PECs (stimula-
tor cells from F1 mice) into the ear of F1 mice. In contrast to
regulator cells from WT mice, regulator T cells from CD1
KO mice that received OVA were unable to suppress the
DTH response (Fig. 2 B). An experiment was performed in
B6 CD1 KO mice (hatched bars) to confirm the role of
NKT cells in ACAID in a genetically homogeneous back-
ground. In this case, effector and stimulator cells were pre-
pared from B6 mice, and then cells were transferred to the
B6 recipient. These results show that NKT cells or other
CD1-dependent populations were needed for the develop-
ment of ACAID in general, and for the generation of the an-
tigen-specific efferent regulatory T cells, in particular.
Adoptive Transfer of NKT Cells and CD11 APCs Reconsti-
tutes the ACAID-inducing Ability in the CD1 KO Mice. To
confirm whether the defect in the CD1 KO mice that led
Figure 3. Effect of NKT cell reconstitution on ability of CD1 KO mice
to develop ACAID. (A) Flow cytometry confirmation of NK and NKT cell
depletion in vitro. Spleen cells from F1 mice were treated with FITC-con-
jugated anti-NK1.1 mAb, biotin-conjugated Ly49C mAbs, and MicroBead-
conjugated anti–mouse pan-NK cell Ab before treatment with anti-FITC
MicroBeads and streptavidin MicroBeads, and exposure to a magnetic field
to remove NK and NKT cells. The negatively selected cells, and the simi-
larly treated whole spleen cell population not exposed to the magnetic field,
were stained with CyChrome 5–conjugated anti–TCR b chain mAb and analyzed by flow cytometry. Fluorescence for CyChrome 5–TCR b chain and
FITC-NK1.1 are shown on the ordinate and abscissa, respectively. The percentage of cells within the NKT cell (square) and the NK cell (rectangle) quad-
rants are listed in the blocks before (whole splenocytes, type 1) and after (NK and NKT depleted, type 2) depletion. (B) Flow cytometry confirmation of
CD11 cell depletion. 7 d after reconstitution with whole spleen cells (type 1) or NK and NKT cell–depleted spleen cells (type 2, Fig. 3 A), five mice from
each reconstituted CD1 KO mouse group were inoculated (ac) with OVA. Column-enriched splenic T cells were harvested 1 wk after ac inoculation, and
CD11 cells were removed. Cells were stained with biotin-conjugated anti-CD1 (1B1), then treated with streptavidin MicroBeads and applied to MiniMACS
columns to deplete CD11 cells. Flow cytometry–generated graphs show the relative number of cells (ordinate) versus the increasing fluorescence channels
(abscissa) that identify PE-streptavidin-biotin–conjugated anti-CD1 mAb–labeled cells. “KO & WT control” shows the fluorescence pattern of splenic T
cells from unreconstituted CD1 KO (open) or WT (shaded) mice; “reconstituted KO” shows the pattern of CD11 cells after reconstitution; “cells for LAT”
shows the pattern of CD11 cells after negative selection. The percentage of CD11 cells is indicated in each of the lower blocks. (C) LAT assay for CD12 T
cell regulator function. CD12 T cells from reconstituted CD1 KO mice (regulator) were cotransferred with effector and stimulator cells from F1 mice into
the ear pinnae of naive F1 mice. Adoptively transferred regulator cells from reconstituted mice that did not receive ac inoculation were used as a control. Ear
swelling measurements (24 h after ear challenge) are shown on the ordinate, and the identity of the cell mixture inoculated into the ear pinnae for each group
(five per group) is indicated below the abscissa. Significant differences (P # 0.05) are indicated by an asterisk.1220 NKT Cells in Immune Deviation
to the failure of ACAID was actually the NKT cell defi-
ciency, we reconstituted CD1 KO mice with whole spleen
cells from WT mice (F1) (containing both NKT cells and
CD11 APCs), or spleen cells immunomagnetically de-
pleted of NK1.11 lymphocytes (that still contained CD11
APCs). The successful depletion of NKT and NK cells was
confirmed by flow cytometry analysis (Fig. 3 A). 7 d after
reconstitution, the mice were inoculated (ac) with OVA,
and after 8 d spleen cells were harvested for T cell enrich-
ment. A typical profile of enriched splenic T cells from re-
constituted CD1 KO mice (Fig. 3 B, bottom left panel)
shows that z4.9% of T cells were donor derived (CD11).
(Total of CD11 cells in the non-T splenic cells was 25%;
data not shown.) To analyze the regulatory potential of the
host CD12 T cells, the spleen cells were further negatively
selected against CD1 expression to yield populations that
were CD12 (Fig. 3 B, bottom right panel). These cells
were then assessed as regulator cells in the LAT assay.
We observed that whole spleen cells were able to recon-
stitute the ACAID-inducing ability of the CD1 KO mice.
In contrast, spleen cells depleted of NKT cells did not re-
store ACAID-inducing ability (Fig. 3 C). Because CD1 is
expressed on all WT bone marrow–derived cells that were
transferred, these results also show that antigen-specific-
efferent regulatory cells that were generated did not express
CD1, indicating that the transferred CD11 NKT cells were
not the effector cell in the regulation of the expression of
DTH. The data support the postulate that NKT cells are
essential in the induction of ACAID, and function by sup-
porting the generation of antigen-specific efferent-regula-
tory T cells.
NKT Cells Are Not Efferent DTH–regulatory Cells. To
confirm that NKT cells do not have a direct role in efferent
regulation of DTH in another way, we depleted cells ex-
pressing NK1.1 antigens from the regulator cell population
before testing in a LAT assay using specific Ab treatment
and magnetic beads selection (Fig. 4 A). Treated cells were
then assessed by flow cytometry before cotransferring with
primed T cells and OVA-pulsed PECs to the ear pinnae.
The results of the LAT assay showed that the NK and
NKT cell–depleted populations retained their DTH-regu-
latory capability. Thus, the efferent-regulatory cell is a con-
ventional NK1.12 T cell. It is known that activated NKT
cells can downregulate their NK1.1 molecules in vitro (35).
Therefore, we were aware that the in vivo–activated NKT
cell may not express NK1.1, and the Ab depletion of
NK1.11 cells treatment may not work. However, as also
shown in Fig. 1, after OVA was inoculated in the ac
NK1.11 T cells were clearly present in the spleen. There-
fore, together with our observations that CD12 T cells
(from CD11 NKT cell–reconstituted CD1 KO mice) can
function as regulators of DTH (Fig. 3 C), these data con-
firm that NKT cells are not direct efferent regulators of
DTH in ACAID.
NKT Cells, Not NK Cells, Are Required for the Induction of
the Regulatory T Cells in ACAID. Another approach to
assess the importance of NKT cells in induction of systemic
tolerance used Abs specific for NK markers to create CD11
mice with selective depletion of the NK1.11 cell popula-
tions. B6 mice were depleted of NKT cells and NK cells,
or NK cells only, and their ability to generate the efferent
regulatory T cell in ACAID was compared to syngeneic
mice treated with isotype control Ab. We reported previ-
ously that it is difficult to remove the NKT cell population
in vivo with Abs to typical NK cell markers (36). Specifi-
cally, the inoculation of mice with anti-NK1.1 mAb or
RaAsGM1 Ab depletes NK cells, but not NKT cells, al-
though they both express the target antigens (36; and Fig. 5
A and B). Because the NKT cells that remained in the
spleens after in vivo anti-NK1.1 mAb treatment expressed
Ly49C (36), we mixed the anti-NK1.1 and anti-Ly49C
Abs and effectively depleted NKT cells in the mice for
these studies (Fig. 5 B). 24 h after the mixed Ab treatment,
Figure 4. Analysis of NKT and NK cells as efferent regulatory DTH
cells in the LAT assay. (A) Flow cytometry confirmation of NKT and NK
cell depletion in vitro. Column-enriched splenic T cells were harvested
from B6 mice 7 d after OVA (ac) inoculation. All NK1.11 cells were re-
moved from the T cell–enriched populations with a magnetic field after
treatment with a mixture of FITC–anti-NK1.1, biotin–anti-Ly49C
mAbs, and anti–pan-NK cell conjugated Microbeads, and anti-FITC and
streptavidin MicroBeads. CyChrome 5–conjugated anti–TCR b chain
and FITC-conjugated anti-NK1.1 cells are shown in the dot plots for
cells before and after treatment. The percentage of labeled cells is shown
next to the square and rectangle for NKT and NK cells, respectively. (B)
The effect of NKT and NK cell depletion on efferent regulation of DTH.
Ear swelling was measured 24 h after cell transfer of the various cell mix-
tures (indicated below the abscissa for each bar) into the ear pinnae of na-
ive syngeneic mice (five per group), and is shown on the ordinate. Signif-
icant differences (P # 0.05) are indicated by an asterisk.1221 Sonoda et al.
mice were inoculated (ac) with OVA, and the differently
treated groups of mice were tested 1 wk later for their abil-
ity to generate efferent-regulatory T cells in a LAT assay.
As expected, the NK-only depleted mice, previously
treated with either RaAsGM1 or anti-NK1.1 mAb, devel-
oped antigen-specific efferent-regulatory T cells (Fig. 5, C
and D), but the NKT and NK cell–depleted mice did not
(Fig. 5 D). Therefore, together with studies in the CD1
KO mice (Fig. 3), these data show that the CD1-depen-
dent cell responsible for the development of systemic toler-
ance and the generation of regulatory T cells in ACAID is
the CD1-dependent NKT cell.
NKT Cell–CD1 Interactions Are Required for Induction
of Efferent-regulatory T Cells in ACAID. Clearly CD1 is
needed for the development of NKT cells, but it is un-
known if CD1 is required for NKT cell function in the
generation of regulatory T cells in ACAID. We reasoned
that if NKT cell interactions with CD1 were required for
ACAID induction, we might be able to block ACAID by
blocking the NKT cell interaction with CD1. Previously,
Figure 5. ACAID in NK and NKT cell–depleted mice.
(A) Flow cytometry confirmation of NK cell depletion. Data
in the dot plots confirm the presence (control) and absence of
NK cells (RaAsGM1 treatment). B6 mice were inoculated
intravenously with RaAsGM1 Ab or purified rabbit IgG.
Column-enriched splenic T cells (includes NK and NKT
cells) were harvested 24 h later and stained with CyChrome
5–conjugated anti–TCR b chain and PE-streptavidin-
biotin–conjugated anti-NK1.1 mAbs, and analyzed by flow
cytometry. The cell population that is analyzed is indicated
above the block, and the percentage of NKT cells and NK
cells is indicated by the square and rectangle, respectively,
within the dot plot shown. (B) Flow cytometry confirmation
that mixed antibody treatment removed NKT as well as NK
cells. B6 mice were inoculated with mouse IgG, anti-NK1.1
mAb, or a mixture of anti-NK1.1 and anti-Ly49C mAbs.
Column-enriched splenic T cells harvested 24 h later were
stained by CyChrome 5–conjugated TCR b chain mAb and
FITC-conjugated goat anti–rabbit and RaAsGM1, and as-
sessed by flow cytometry. (C) LAT assay for role of NK cells
in generation of T-regulatory cell in ACAID. Mice (five per
group) were inoculated (ac) with OVA 24 h after treatment
with purified rabbit IgG, or RaAsGM1 Ab. 7 d later, column-
enriched splenic T cells were harvested from the ac-inocu-
lated mice (regulator), and cotransferred with effector and
stimulator cells (from B6 mice) into ear pinnae of five syn-
geneic naive mice. Ear swelling measurements (24 h after ear
challenge) are shown on the ordinate. The phenotype of the
cell mixtures that were injected into the ear pinnae is indi-
cated below the abscissa for each bar. Significant differences
(P # 0.05) are indicated by an asterisk. (D) LAT assay to test
the role of NKT cells in generation of T-regulatory cells.
Each of five mice was treated with mouse IgG, anti-NK1.1
mAb, or a mixture of anti-NK1.1 and anti-Ly49C mAb
treatment 1 d before inoculation (ac) with OVA. 7 d later,
column-enriched splenic T cells were harvested from the ac-inoculated mice (regulator), and cotransferred with effector and stimulator cells (from B6
mice) into ear pinnae of five syngeneic naive mice. Ear swelling measurements (24 h after ear challenge) are shown on the ordinate, and the phenotype of
the cell mixture inoculated into the ears is indicated below the abscissa for each group (five per group) indicated by the bar. Significant differences (P #
0.05) are indicated by an asterisk.1222 NKT Cells in Immune Deviation
anti-CD1 mAbs (3C11) were successfully used in vitro to
block NKT cell–CD1 interactions (31). Therefore, mice
were treated with anti-CD1 mAb 1 d before being inocu-
lated (ac) with OVA and 8 d before harvesting the spleens,
dissociating the cells, and column-enriching the splenic T
cells for use as regulator cells in a LAT assay. 24 h after anti-
CD1 treatment (3C11), dissociated spleen cells were stained
with a different Ab for CD1 (1B1) to assess the presence of
CD11 cells in the spleen. Flow cytometry analyses showed
that the Ab treatment did not alter the ratio or absolute
number of CD11 cells. In addition, anti-CD1 mAb treat-
ment of mice did not alter the ratio or absolute number of
NKT and NK cells (stained by anti–TCR-b and anti-
NK1.1), T cells (stained by anti-CD3), B cells (stained by
anti-B220), and macrophages (anti–Mac-1) in their spleens
(data not shown). Groups of mice treated with control Ab
developed antigen-specific efferent-regulatory T cells, but
mice treated with anti-CD1 mAb did not (Fig. 6). Because
the Ab treatment did not eliminate CD11 cells, the most
likely explanation is that an interaction between NKT cells
and CD1 was blocked by the anti-CD1 mAb. Thus, we pos-
tulate that an interaction between the NKT cell and the CD1
molecule is required for the NKT cell to function in ACAID.
Intravenously Induced Systemic Tolerance Is Not Defective in
CD1 KO Mouse. Since antigen inoculated into the ac is
carried to the spleen, an argument could be made that there
are few differences between the induction mechanisms of
ACAID and the mechanisms involved in intravenously in-
duced systemic tolerance. In fact, it could be argued that
the leakage of antigen from the venules in the eye into the
blood during ACAID induces intravenous tolerance. How-
ever, differences between the mechanisms involved in im-
mune deviation via the ac or intravenous route have been
reported (13). It has also been reported that intravenously in-
duced tolerance generates CD81 afferent-regulatory T cells
in contrast to ACAID, which generates both CD41 afferent-
regulatory T cells and CD81 efferent-regulatory T cells (14).
CD1 KO mice and WT mice were inoculated ac or in-
travenously with OVA 7 d before subcutaneous sensitiza-
tion with OVA and CFA and testing for DTH by challeng-
ing 14 d later with OVA-pulsed PECs into the ear. As
before, ear swelling was measured 24 and 48 h later. As ex-
pected, WT mice developed immune deviation regardless
of the route of inoculation (Fig. 7). Importantly, in contrast
to the inability of CD1 KO mice to develop immune devi-
ation when inoculated ac, intravenously treated CD1 KO
mice were fully capable of developing immune deviation, and
showed reduced ear-swelling responses (Fig. 7). Therefore,
NKT cells do not participate in intravenously induced im-
mune deviation, and ACAID is indeed a separate entity, with
unique and locally maintained mechanisms of regulation.
Discussion
This report shows that NKT cells (a) are required for the
development of ACAID; (b) are specifically required for
the generation of an efferent-regulatory T cell; (c) may in-
teract with a CD1-expressing cell to mediate regulatory
mechanisms for suppressing DTH responses in ACAID;
and (d) are not required for intravenous tolerance. In addi-
tion, a relationship between ACAID and self-tolerance is
suggested by reports that induction of ACAID in mice
both prevented the onset of and also suppressed ongoing
experimental autoimmune uveitis (37). Furthermore, while
several previously published reports imply a role for NKT
cells in preventing certain autoimmune disease in humans
Figure 6. In vivo blocking of NKT cell–CD1 interaction abrogated
the ACAID. Five B6 mice were inoculated intravenously with rat IgM or
anti-CD1 (3C11) Abs 1 d before ac inoculation with OVA. 7 d later, col-
umn-enriched splenic T cells harvested from ac-inoculated mice (regula-
tor) were cotransferred with effector and stimulator cells into the ear pin-
nae of naive syngeneic mice (five per group). Ear swelling measurements
from B6 mice (24 h after ear challenge) are shown on the ordinate, and
cell mixture inoculated is indicated below each bar on the abscissa. Signif-
icant differences (P # 0.05) are indicated by an asterisk.
Figure 7. Comparison of ACAID versus intravenously-induced toler-
ance in CD1 KO mice. CD1 KO mice and control WT mice (five mice
per group) were inoculated ac or intravenously with OVA 7 d before
subcutaneous sensitization with OVA and CFA. OVA-inoculated mice
were challenged in their ear pinnae with OVA-pulsed PECs from F1
mice 7 d after sensitization. Ear swelling measurements (24 h after ear
challenge) are shown on the ordinate, and treatment of mice is indicated
below the abscissa for each group (five per group) indicated by the bar.
Significant differences (P # 0.05) are indicated by an asterisk.1223 Sonoda et al.
(38, 39) and in mice (20, 40, 41), the mechanisms through
which NKT cells might regulate autoimmunity remain un-
clear. Therefore, these results indicate that the autoimmunity
associated with NKT cell defects (such as type 1 diabetes,
scleroderma) may be mediated by disruption of organ-spe-
cific tolerance mechanisms that are similar to those mediat-
ing systemic tolerance to antigens introduced through im-
mune-privileged sites.
The systemic tolerance to antigens introduced into the
ac (ACAID) involves several steps. In the initial step, anti-
gen introduced into the ac is carried to the spleen by spe-
cialized eye-derived F4/801 APCs (42). A CD81 efferent
or effector stage regulatory T cell that can suppress a subse-
quent DTH response to the specific antigen is then gener-
ated. This study further shows that CD1-reactive NKT
cells are required for the generation of the ACAID regula-
tory T cell. On the other hand, the LAT studies of CD1
KO mice reconstituted with CD11 NKT cells show that
CD1d expression by ACAID efferent-regulatory cells was
not necessary (Fig. 3 B and C). Anti-CD1 blocking experi-
ments nonetheless indicate a role for CD1, presumably
functioning as a ligand for NKT cells in ACAID. There-
fore, we suggest that the critical CD1-dependent interac-
tion is between the NKT cell and the specialized ac-
derived APC, and that NKT cell interactions with particular
APCs may similarly be defective in some autoimmune dis-
eases associated with loss of NKT cell function.
The ac contains aqueous humor that is filled with a mix-
ture of immunosuppressive components including TGF-b
(3–6, 43). Moreover, we observed that addition of TGF b2
to thioglycolate-induced PECs in vitro induced an increased
expression of their CD1d molecules (Sonoda, K.-H., and J.
Stein–Streilein, unpublished observations). Thus, the eye-
derived APCs may similarly express increased levels of CD1,
and thereby stimulate NKT cells in the spleen. Alternative,
and not mutually exclusive, hypotheses are that NKT cells
are activated by a CD1-presented endogenous lipid anti-
gen, accessory molecule, or cytokine produced by the APC.
A further alternative is that the NKT cells recognize
CD1d expressed by another cell type in the spleen. Such a
possible CD11 NKT cell stimulator in the spleen is the
marginal zone B cell. Niederkorn and colleagues showed
that splenic B cells are needed for ACAID, and suggested
that eye-derived APCs “hand over” their antigen and allow
the splenic B cells to induce ACAID (44, 45). Consistent
with this hypothesis is the observation that the APCs in the
spleen that express the highest density of CD1 are the mar-
ginal zone B cells (46).
Activated NKT cells may produce large amounts of a va-
riety of cytokines (35) that, in the splenic microenviron-
ment, likely contribute to the development of the efferent-
regulatory T cell in ACAID. Cytokines, such as IL-4, may
directly modulate activity of the efferent-regulatory cell.
While IL-4 is most commonly thought to mediate NKT
cell–dependent T cell regulation, we do not propose it to
be the critical cytokine in NKT cell–dependent generation
of the efferent-regulatory T cell since ACAID occurs in IL-4
KO mice (16, 47, 48). Another potentially important cy-
tokine, already commonly associated with the development
of ACAID, is TGF-b (43). A report has been published
showing NKT cell production of TGF-b (49), and another
shows that TGF-b may modulate APC function (50).
Thus, the possibility arises that NKT cells respond to the
CD1 or other signals by upregulating TGF-b production
or its conversion from latent to active form. Strengthening
this possibility is a recent report by Kosiewicz et al. show-
ing that both CD41 CD82 and CD42 CD82 (double neg-
ative, DN) T cells from ACAID spleens produced TGF-b
(16). NKT cells are notably either CD41 or DN (22).
A significant technical observation in this study is that in
our hands NKT cells are resistant to in vivo antibody treat-
ments known to remove NK cells. While others report re-
moval of NKT cells by anti-NK1.1 mAb (51, 52), we
could only eliminate NK cells and not NKT cells with ei-
ther anti-NK1.1 mAb or RaAsGM1 Ab alone. However,
when we used a mixture of Abs, we effectively eliminated
NKT cells as well as NK cells. These results were not sur-
prising, as we previously reported that while activating ap-
optosis in NK cells, the NK antigen–specific (anti-NK1.1)
Ab treatment activated IL-4 synthesis in NKT cells (36). In
our laboratory, when the same Ab was used to label cells
for flow cytometry that was used for elimination, we could
not find the cells because the antigen was either masked or
downregulated. Thus, we consistently used different mAbs
for depletion studies and the flow cytometric analyses.
In contrast to ACAID, intravenous tolerance could be
induced in CD1 KO mice. The relationship between intra-
venous tolerance and ACAID is unclear, but intravenous
tolerance does differ from ACAID in several respects. The
intravenous administration of antigen cannot suppress the
immune response in previously immunized hosts, whereas
presentation of antigen via the ac does downregulate ongo-
ing DTH responses in previously immunized hosts (53).
Moreover, ACAID is mediated by both CD41 afferent
regulatory T cells and CD81 efferent regulatory T cells
(13), whereas intravenously induced tolerance only re-
quired CD81 afferent-regulatory cells (14). (In fact, be-
cause intravenous tolerance mechanism does not require an
efferent-regulatory cell, we could not test the intravenous
tolerance capability of CD1 KO mice in a LAT assay.) It
is proposed that intravenous tolerance reflects the intrinsic
response of T cells to antigen in the absence of costimula-
tory molecules, and therefore may not require additional
cells (54). In contrast, this report clearly shows that ACAID
involves interactions between multiple cells, a process that
may be necessary in order to suppress established immune
responses. A recent paper by Zeng et al. suggests that NKT
cells may be responsible for assisting the generation of anti-
gen-specific regulatory T cells in the bone marrow, perhaps
to regulate immune responses to self-antigens displayed on
other bone marrow–developing cells (55). Thus, it seems
likely that CD1-reactive NKT cells may not only be
unique regulators of self-reactivity in immune privileged
sites (ACAID), but also may contribute to self-tolerance
through regional specialization in a variety of organs, tis-
sues, and microenvironments in general.1224 NKT Cells in Immune Deviation
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